CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Treatment and prophylaxisWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug466 COVID-19 Specific T Cell derived exosomes (CSTC-Exo) Wiki 1.00
drug2309 Standard Public Health measures Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)

This study is a research project to evaluate the efficacy of hydroxychloroquine for post-exposure prophylaxis and early treatment of Covid-19. The intervention entails administering prophylactic hydroxychloroquine to all contacts (Study 1) and treating non severe confirmed cases with hydroxychloroquine (Study 2).

NCT04304053 COVID-19 Drug: Treatment and prophylaxis Other: Standard Public Health measures

Primary Outcomes

Description: Incidence of secondary PCR confirmed symptomatic Covid-19 episodes among contacts after high risk PCR+ exposure

Measure: Study 1- Clinical and virological outcome in exposed contacts

Time: Up to 14 days after start of treatment

Description: Incidence of symptomatically compatible or a PCR-positive result regardless of symptoms

Measure: Study 1- Transmission of SARS-CoV-2 in exposed contacts

Time: Up to 14 days after start of treatment

Description: Reduction of viral RNA load in nasopharyngeal swabs at days 3, and 7 after treatment start.

Measure: Study 2- Virological outcome in index cases

Time: Up to 7 days after start of treatment

Description: Time from randomization to complete resolution of symptoms at an extended 28-days follow-

Measure: Study 2- Clinical outcome in index cases

Time: Up to 28 days after start of treatment

No related HPO nodes (Using clinical trials)